Hologic divests drug
This article was originally published in The Gray Sheet
Executive Summary
Women's health device maker divests Gestiva, its "non-core" drug for the prevention of preterm birth, to KV Pharmaceutical for $82 million in a deal announced Jan. 22. The drug, which is pending FDA approval, was part of Hologic's October purchase of cervical cancer test firm Cytyc (1"The Gray Sheet" May 28, 2007, p. 10)
You may also be interested in...
Hologic/Cytyc Merger Combines Diverse Women’s Health Device Portfolios
The combination of mammography device maker Hologic and cervical cancer test firm Cytyc will create a women's health powerhouse with $1.44 billion in combined annual revenues
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.